HC Wainwright Has Strong Estimate for ALDX FY2026 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Aldeyra Therapeutics in a report issued on Tuesday, November 10th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will earn ($0.27) per share for the year, up from their previous forecast of ($0.39). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at $0.01 EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.29 EPS.

Other research analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, September 29th. Finally, Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.00.

Aldeyra Therapeutics Trading Up 3.5%

Shares of ALDX stock opened at $0.65 on Thursday. Aldeyra Therapeutics has a 12 month low of $0.53 and a 12 month high of $5.93. The stock has a 50-day moving average price of $1.00 and a 200 day moving average price of $2.14.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Chicago Partners Investment Group LLC bought a new position in shares of Aldeyra Therapeutics in the 1st quarter worth $33,000. Hikari Power Ltd acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth $43,000. Two Sigma Securities LLC bought a new stake in Aldeyra Therapeutics in the second quarter valued at about $70,000. Bank of America Corp DE bought a new stake in Aldeyra Therapeutics in the second quarter valued at about $72,000. Finally, Squarepoint Ops LLC acquired a new position in Aldeyra Therapeutics in the second quarter valued at about $200,000. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases. Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis.